Table 1.
Proportion of samples stratified by AJCC stage detected with each individual assay and all combinations thereof
| % samples detected (95% confidence interval) | |||||
| Assay type | Stage IA, 12 cases | Stage IB, 17 cases | Stage IIA, 22 cases | Stage IIB, 170 cases | Stage I and II, 221 cases |
| ctDNA | 25 (5–57) | 0 (0–20) | 18 (5–40) | 35 (28–42) | 30 (24–36) |
| CA19-9 | 17 (2–48) | 41 (18–67) | 36 (17–59) | 54 (46–62) | 49 (43–56) |
| CEA + HGF + OPN | 25 (5–57) | 6 (0–29) | 14 (3–35) | 19 (14–26) | 18 (13–24) |
| ctDNA + CA19-9 | 33 (10–65) | 41 (18–67) | 50 (28–72) | 65 (58–72) | 60 (53–67) |
| ctDNA + CEA + HGF + OPN | 33 (10–65) | 6 (0–29) | 32 (14–55) | 47 (39–55) | 42 (35–48) |
| CA19-9 + CEA + HGF + OPN | 25 (5–57) | 47 (23–72) | 36 (17–59) | 59 (52–67) | 54 (47–61) |
| Combination assay | 33 (10–65) | 47 (23–72) | 50 (28–72) | 69 (62–76) | 64 (57–70) |